Phaseline

Targets › RPE65

RPE65 (Retinoid isomerohydrolase): drug programs, companies and trials

3 programs from 3 companies in 6 trials: 4 Phase 1, 2 Phase 3; Ophthalmology; next expected readout Oct 2027.

Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore. (UniProt, Q16518)

Open in Phaseline: the race on RPE65, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Spark TherapeuticsVoretigene Neparvovec
Retinoid isomerohydrolase exogenous gene
RPE65Phase 3Inherited Retinal Dystrophy Due to RPE65 Mutations; Leber Congenital AmaurosisOct 2027
Innostellar BiotherapeuticsLX101
Gene therapy for RPE65 mutations
RPE65Phase 3Inherited Retinal Dystrophy Associated With RPE65 Mutations; Inherited Retinal DystrophyDec 2027
Frontera TherapeuticsFT-001
Subretinal AAV5-delivered RPE65 gene therapy
RPE65Phase 1Biallelic RPE65 Mutation-associated Retinal DystrophyNov 2029

Conditions

Inherited Retinal Dystrophy Associated With RPE65 Mutations (2) Inherited Retinal Dystrophy (1) Biallelic RPE65 Mutation-associated Retinal Dystrophy (1) Inherited Retinal Dystrophy Due to RPE65 Mutations (1) Leber Congenital Amaurosis (1)

Modalities

other (3)

Companies

Innostellar Biotherapeutics (1) Frontera Therapeutics (1) Spark Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.